Three paliperidone palmitate doses or placebo for schizophrenia
About this title
Read the official source — NCT00590577Researchers compared Paliperidone palmitate 25 mg eq., Paliperidone palmitate 100 mg eq., Paliperidone palmitate 150 mg eq. and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared Paliperidone palmitate 25 mg eq., Paliperidone palmitate 100 mg eq., Paliperidone palmitate 150 mg eq. and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Anaheim and 65 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 652
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Malaysia, Romania, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00590577
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Anaheim, United States · Cerritos, United States · Escondido, United States
64 more locations
- Glendale, United States
- La Palma, United States
- Los Angeles, United States
- National City, United States
- San Diego, United States
- Santa Ana, United States
- Jacksonville, United States
- Kissimmee, United States
- Miami, United States
- North Miami, United States
- Atlanta, United States
- Hoffman Estates, United States
- Kingsport, United States
- Wichita, United States
- Lake Charles, United States
- Shreveport, United States
- Baltimore, United States
- Rockville, United States
- Cedarhurst, United States
- New York, United States
- Olean, United States
- Cincinnati, United States
- Moore, United States
- Charleston, United States
- Austin, United States
- Houston, United States
- San Antonio, United States
- Arlington, United States
- Richmond, United States
- Johor Bahru, Malaysia
- Kota Bharu, Malaysia
- Kuala Lumpur, Malaysia
- Perak, Malaysia
- Brasov, Romania
- Bucharest, Romania
- Craiova, Romania
- Iași, Romania
- Oradea, Romania
- Sibiu, Romania
- Tg Mures, Romania
- Kazan', Russia
- Lipetsk, Russia
- Moscow Russia, Russia
- Nizny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- St-Petersburg Na, Russia
- St-Petresburg, Russia
- Yaroslavl, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Gwangju, South Korea
- Inchun, South Korea
- Seoul, South Korea
- Changhua, Taiwan
- Hualien City, Taiwan
- Kaohsiung City, Taiwan
- Taipei, Taiwan
- Dnipro, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Paliperidone palmitate 25 mg eq., Paliperidone palmitate 100 mg eq., Paliperidone palmitate 150 mg eq. and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo and Paliperidone palmitate 100 mg eq..
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
